CARLSBAD, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals,
Inc. (Nasdaq: ISIS) announced today that its majority-owned subsidiary, Ibis
Biosciences, Inc. (Ibis), has been awarded two new Phase 2 Small Business
Innovation Research (SBIR) grants and a new government contract totaling up to
"The ongoing government support we received enables us to broaden the utility of the T5000 System in new applications such as blood supply screening, where there is a need to expand the breadth of screening technologies to identify all important organisms," said Michael Treble, President of Ibis and Vice President of Isis. "The additional contract funding from DHS-S&T will expedite the expansion of our microbial database of pathogens."
The SBIR grants fund the application of the Ibis T5000 Biosensor System into new areas of biothreat detection, including the identification of bacteria, viruses and parasites that might cause disease in active military forces or contaminate the military blood supply.
"We have earned nearly
ABOUT THE IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.
Ibis Biosciences, Inc., a majority-owned subsidiary of Isis Pharmaceuticals, has developed and is commercializing the Ibis T5000(TM) Biosensor System for rapid identification and characterization of infectious agents. The Ibis T5000 is currently intended for research use only and not for use in diagnostic procedures. It is capable of identifying virtually all bacteria, viruses and fungi, and can provide information about drug resistance, virulence and strain type of these pathogens. Commercial applications for the Ibis T5000 Biosensor System include epidemiologic surveillance, monitoring of pandemic diseases, identification of emerging or previously unknown pathogens, forensic characterization of human samples, identification of sources of hospital-associated infections, and, in the future, human infectious disease diagnostics. Ibis develops, manufactures and markets Ibis T5000 instruments and assay kits, including through its partner, Bruker Daltonics, a subsidiary of Bruker BioSciences Corporation. Additional information about Ibis can be found by selecting the Ibis link from Isis' homepage at http://www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.